Litcius/Paper detail

De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma

Diana D. Shi, Milan R. Savani, Michael M. Levitt, Adam C. Wang, Jennifer E. Endress, Cylaina Bird, Joseph Buehler, Sylwia A. Stopka, Michael S. Regan, Yu‐Fen Lin, Vinesh T. Puliyappadamba, Wenhua Gao, Januka Khanal, Laura Evans, J Lee, Lei Guo, Yi Xiao, Min Xu, Bofu Huang, Rebecca B. Jennings, Dennis M. Bonal, Misty S. Martin-Sandoval, Tammie Dang, Lauren C. Gattie, Amy Cameron, Sung-Woo Lee, John M. Asara, Harley I. Kornblum, Tak W. Mak, Ryan Looper, Quang‐Dé Nguyen, Sabina Signoretti, Stefan Gradl, Andreas Sutter, Michael Jeffers, Andreas Janzer, Mark A. Lehrman, Lauren G. Zacharias, Thomas P. Mathews, Julie-Aurore Losman, Timothy E. Richardson, Daniel P. Cahill, Ralph J. DeBerardinis, Keith L. Ligon, Lin Xu, Peter Ly, Nathalie Y.R. Agar, Kalil G. Abdullah, Isaac S. Harris, William G. Kaelin, Samuel K. McBrayer

2022Cancer Cell129 citationsDOIOpen Access PDF

Topics & Concepts

Isocitrate dehydrogenaseGliomaDihydroorotate dehydrogenaseMutantBiologyPyrimidine metabolismIDH1Cancer researchEnzymeBiochemistryPurineGeneBiochemical and Molecular ResearchGlioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma | Litcius